Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin in hemodynamically stable patients with worsening heart failure
2017-002774-39Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing Sotagliflozin with Placebo (2 arms). Primary endpoint: Safety and tolerability (adverse events). Started Oct 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2017-002774-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002774-39.